SEC Filing Summary: Form 13F Information Table
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted to the U.S. Securities and Exchange Commission. The document details equity holdings as of the reporting period ending June 30, 2025. While the metadata references "Takeda Pharmaceutical Co Ltd," the filing content lists specific holdings in various biotechnology and healthcare companies, indicating this is a disclosure of investment positions rather than a corporate earnings report for Takeda itself.
Key Financial Metrics and Holdings
The filing discloses long-only equity positions (Shares) with no put or call options reported. The total value of the reported positions is approximately $17.2 million. Key holdings include:
- HilleVax, Inc.: 13,381,160 shares valued at $6,724,000 (Largest position).
- Ovid Therapeutics, Inc.: Two separate entries totaling 2,485,380 shares valued at $7,531,996.
- Equillium, Inc.: 575,233 shares valued at $1,824,977.
- Xilio Therapeutics, Inc.: 1,002,935 shares valued at $1,475,121.
- Turnstone Biologics: 321,601 shares valued at $895,824.
- Shattuck Labs, Inc.: 408,267 shares valued at $515,619.
- Rani Therapeutics Holdings, Inc.: 104,419 shares valued at $203,190.
- American Well Corporation: 691,050 shares valued at $77,733.
- Third Harmonic Bio, Inc.: 200,014 shares valued at $36,835.
- Lyell Immunopharma, Inc.: 363,906 shares valued at $41,165.
- Standard Biotools, Inc.: 19,818 shares valued at $16,515.
Voting Authority: Most positions are reported with "DFND" (Discretionary) authority. One position in Ovid Therapeutics is reported with "SOLE" authority. No "Shared" or "None" voting authority is listed for the majority of holdings.
Material Changes
The filing text does not provide comparative data from the prior quarter or year. Therefore, material changes in share counts or valuation versus the prior comparable period cannot be determined from this document alone.
Guidance, Outlook, and Risks
This Form 13F is a statutory disclosure of holdings and does not contain management commentary, financial guidance, outlook, or specific risk factors regarding the issuer's operations. The filing includes a standard disclaimer that the SEC has not reviewed the information for accuracy or completeness.
Investor Verification Checklist
- Verify the identity of the reporting manager, as the metadata mentions Takeda but the holdings are in smaller biotech firms.
- Confirm the total aggregate value of the portfolio against the sum of individual line items ($17.2M).
- Check the "DFND" vs. "SOLE" voting authority distinctions for Ovid Therapeutics to understand control levels.
- Review the CUSIP numbers to ensure the correct securities are identified, particularly for Xilio Therapeutics (formerly Akrevia).
- Note that no debt, cash flow, or margin data is present as this is an equity holding report, not an income statement.